U.S. Markets open in 8 hrs 49 mins

BioCryst Pharmaceuticals, Inc. (BCRX)

NASDAQ Global Select - NASDAQ Global Select Delayed Price. Currency in USD
Add to watchlist
4.21+0.11 (+2.68%)
At close: 4:00PM EDT
People also watch
NVAXHEBVICLARRYAGEN
  • H
    Horowitz
    Horowitz

    SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA

    Sonoma Pharma (Nasdaq: SNOA)

    Market Cap: 22.1 Million
    Cash: $12.6 Million
    Price: $5.15

    Shares Out : 4.3 Million

    Presentation
    http://ir.sonomapharma.com/common/download/download.cfm?companyid=ocls&fileid=945547&filekey=F57B6874-6CD1-4205-A160-8E08BBB7A928&filename=SonomaPharma_Investor_presentation_13June2017.pdf

    Fact Sheet
    http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf

    Driving to commercial EBITDAS breakeven, without dilution

    Grow current product portfolio with all sales people

    •Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
    •Mondoxyne for severe acne –launched late 2015
    •Ceramax for skin repair in atopic dermatitis–launched in April 2016
    •SebuDerm for seborrhea dermatitis –launched in November 2016

    Launch 3 New Products –our product pipeline –one every other quarter

    •Launching Loyon–Fall 2017
    •Ceramax in foam and gel forms –Q4 2017 & Q1 2018

    Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.

    We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.

  • H
    Henry
    Henry
    I an out of this stock, lost 30%
  • R
    Roderick
    Roderick

    This is where I find the top NASDAQ & NYSE Trade Ideas ---> www.T0pm@rketgainers.c0m

  • J
    Jeromy
    Jeromy

    www.PennySt0ckl0l.org is one of the best “alerts” services I have found. Just sign up and watch from the sidelines, you will see!

  • A
    Alexandra
    Alexandra
    If we are to go off the RSI then you could argue that a pull back next day or so could occur on BCRX before rallying up. awe*some*sto-ck*s just allerted a new stock - it beats having to dig online yourself for new stock ideas.
  • r
    ron
    ron
    Sweet Jesus! 13% plunge
  • M
    Myron
    Myron
    Big Galning, Low-Prlced NASDAQ and NYSE Alerts ---> PennyStocklOl.org
  • A
    Aldon
    Aldon

    www.PennySt0ckl0l.org is one of the best “alerts” services I have found. Just sign up and watch from the sidelines, you will see!

  • C
    China Education Resources CHN V
    China Education Resources CHN V
    bad movement today. hoping for bounce similar to Q1.....
  • H
    Henry
    Henry
    Nice move today
  • P
    Pharmaherooooooo
    Pharmaherooooooo

    KTOV = Mcap $16 Mil /Cash $17 Mil /Low float O/S 10 M / NDA submission for Big Drug this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    “KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients’ risk of suffering a heart attack or stroke, while also reducing cost for payers. There is currently no single medication on the market that treats both osteoarthritis pain and hypertension and thus, KIT-302 will be the only NSAID indicated both to treat pain and to reduce the risk of heart attack, stroke and death.”

    Pain medications for osteoarthritis account for billions of dollars in annual sales globally. Most pain medications for osteoarthritis, including celecoxib which had global sales of $2.7 billion in 2014, are non-steroidal anti-inflammatory drugs (NSAIDs) which have the side effect of elevating blood pressure, and increasing the risk of heart attacks, strokes and death. Of the 27 million Americans who live with osteoarthritis, 13.5 million also suffer from hypertension, which also increases the risk of heart attack, stroke, and death.

  • r
    richard
    richard
    DO I HAVE THIS BCRX PICTURE CORRECT.....MEANING ,
    There was a secondary offering middle march for $8.50... & now we are at $5.41 ??? Did the bankers do their home work to protect there clients ??? I do not think they did... Well BCRX must now be a DEAL or A Bad Deal...... It will be important to see which FUNDS increased or decreased there position..... Being that R A Cap & Brothers are in , this must be a Deal...at todays price... Any thoughts on this ???
  • r
    richard
    richard
    I can not find the recent Secondary Offering Share price.... What was the share price of the last offering,,, THX
  • A
    Anonymous
    Anonymous

    [!] Just updated to now display all available spreads - Option traders pay a visit to CreditSpreads.io, absolutely free live table of statistically gainful option credit spreads for the next month, sometimes including spreads for BCRX! High probability option credit spreads offer you an effective way to invest with defined risk and the max profit gained up front. CreditSpreads.io lazer-targets solely the credit spreads which fulfill its strict requirements for probability and profit, and ensures continued profitability by warning you of any upcoming situations which could affect the trade. http://www.creditspreads.io

    CreditSpreads.io
    Sustainable, high probability, defined risk stock option trading opportunities.
    www.creditspreads.io
  • A
    Anonymous
    Anonymous

    [!] Just upgraded to now display all available spread combinations - Option spread traders check out CreditSpreads.io, cost free live feed of mathematically gainful option credit spreads for the following month, sometimes including spreads for BCRX! High probability option credit spreads provide you with a solution to trade with determined risk and the max profit gained up front. CreditSpreads.io lazer-targets solely the credit spreads which satisfy its rigid standards for risk and profit, and ensures continued profitability by warning you of any future situations which may affect the trade. http://creditspreads.io

    CreditSpreads.io
    Sustainable, high probability, defined risk stock option trading opportunities.
    creditspreads.io
  • r
    richard
    richard

    Monster Microcaps Alert to BCRX shareholders. Clean Energy Technologies Moving broke out 4 weeks ago and is beginning to move again - CETY - price today $.02. Price target $.20 by year end. Clean Energy Technologies. CETY recently announced expansion with their Europe Sales and Service Center for Europe new sales and to serve 65 existing customers with CETY’s General Electric clean energy Heat Recovery Systems and just announced they have already sold the first of SEVERAL HUNDRED units to come over next 24 months.

    Each CETY Heat Recovery System sells for $300,000 and market demand is several BILLION DOLLARS.

    CETY purchased Heat Recovery Systems Division from General Electric and products are now very attractive to huge unmet markets and can achieve over $250 million in sales within the next 2 years. Demand for conversion of wasted heat to electrical energy in big applications is VERY LARGE AND UNMET.

    https://finance.yahoo.com/news/clean-energy-technologies-inc-secures-144700111.html

    Clean Energy Technologies, Inc. Secures New Order for Waste Biomass Application in Europe
    COSTA MESA, Calif., July 12, 2017 /PRNewswire/ -- Clean Energy Technologies, Inc. (CETY) announced today that its subsidiary Heat Recovery Solutions has secured a new Clean CycleTM generator order for a Waste Biomass application in Europe. Growing d
    finance.yahoo.com
  • B
    B-rad
    B-rad
    Anyone recognize the clockwork short action at open? Every other day it drops 4-5% right after open only to recover at close meaning the shorts are busy strobing their sells. If what I'm saying is true, watch the Wednesday drop from 5.54 to 5.34 before the eventual close near 5.60.
  • A
    Anonymous
    Anonymous

    Option traders visit CreditSpreads.io, totally free live feed of mathematically profitable option credit spreads for the coming four weeks, sometimes including spreads for BCRX! High probability option credit spreads offer you a technique to invest with defined risk and the max profit received right away. CreditSpreads.io targets solely the credit spreads which meet its strict requirements for probability and profit, and contributes to continued profitability by telling you of any impending situations that may affect the trade. www.creditspreads.io

    CreditSpreads.io
    Sustainable, high probability, defined risk stock option trading opportunities.
    www.creditspreads.io
  • C
    China Education Resources CHN V
    China Education Resources CHN V
    Nice upside today on the 4th of July weekend. will there be fireworks this week with the aebola virus outbreak????
  • B
    BioNap
    BioNap
    (AXSM) Mcap $90 M /Cash $55 M / 5x Phase 3 programs in various indications targeting huge Markets with first results in Q3 2017 =10+ BAGGER ....GLTA ! Please readand realize the brutal potential !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$3.90

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.